Erratum: The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: Association with CYP2D6 genotype and serum endoxifen levels (Cancer Chemotherapy and Pharmacology DOI: 10.1007/s00280-012-2034-4);The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: Association with CYP2D6 genotype and serum endoxifen levels

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 3, 2013, Pages 593-601

  Opdam, F L ^a   Dezentje, V O ^a   Den Hartigh, J ^a   Modak, A S ^b   Vree, R ^c   Batman, E ^e   Smorenburg, C H ^d   Nortier, J W R ^a   Gelderblom, H ^a   Guchelaar, H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CAMBRIDGE ISOTOPE LABORATORIES INC   (United States)

^c Diaconessenhuis Leiden   (Netherlands)

^d Northwest Clinics   (Netherlands)

^e Internal Medicine   (Netherlands)

Author keywords

Breath test; Dextromethorphan; Endoxifen; Genotype; Phenotype; Tamoxifen

Indexed keywords

CARBON 13; CITALOPRAM; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; ENDOXIFEN; PAROXETINE; TAMOXIFEN; 4-HYDROXY-N-DESMETHYLTAMOXIFEN; ANTITUSSIVE AGENT; DIAGNOSTIC AGENT; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREATH ANALYSIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURGERY; CLINICAL TRIAL; CYP2D6 GENE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; EARLY CANCER; FEMALE; GENE; GENE ACTIVITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHENOTYPE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; STEADY STATE; ADOLESCENT; BLOOD; BREAST TUMOR; ENZYMOLOGY; GENETICS; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTITUSSIVE AGENTS; BREAST NEOPLASMS; BREATH TESTS; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES; TAMOXIFEN; YOUNG ADULT;

MLCS; MLOWN;

EID: 84875819055     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2065-x     Document Type: Erratum

References (47)

1. Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771-784
2. Ohshiro K, Schwartz AM, Levine PH, Kumar R (2012) Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling. PLoS One 7:e30725
3. Furr BJ, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205 (Pubitemid 14015738)
4. Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075 (Pubitemid 39108928)
5. Johnson MD, Zuo H, Lee KH et al (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159 (Pubitemid 38987269)
6. Lim YC, Desta Z, Flockhart DA, Skaar TC (2004) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471-478 (Pubitemid 40568978)
7. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC (2009) The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69:1722-1727
8. Gjerde J, Gandini S, Guerrieri-Gonzaga A et al (2012) Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res Treat 134:693-700
9. Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR (2003) Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chrom B Analyt Technol Biomed Life Sci 791:245-253 (Pubitemid 36638757)
10. Stearns V, Johnson MD, Rae JM et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764 (Pubitemid 38008898)
11. Singh MS, Francis PA, Michael M (2011) Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast 20:111-118
12. Dezentje VO, Guchelaar HJ, Nortier JWR, van de Velde CJH, Gelderblom H (2009) Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 15:15-21
13. Goetz MP, Rae JM, Suman VJ et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318
14. Schroth W, Antoniadou L, Fritz P et al (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193 (Pubitemid 350232249)
15. Damodaran SE, Pradhan SC, Umamaheswaran G, Kadambari D, Reddy KS, Adithan C (2012) Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother Pharmacol 70:75-81
16. Kiyotani K, Mushiroda T, Imamura CK et al (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28:1287-1293
17. Nowell SA, Ahn JY, Rae JM et al (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249-258 (Pubitemid 40903087)
18. Wegman P, Vainikka L, Stal O et al (2005) Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7:R284-R290
19. Rae JM, Drury S, Hayes DF (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452-460
20. Regan MM, Leyland-Jones B, Bouzyk M et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104:441-451
21. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104:1264-1268
22. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S (2007) Genetic variants of Cyp3A5, Cyp2D6, Sult1A1, Ugt2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9:R7
23. Madlensky L, Natarajan L, Tchu S et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718-725
24. Borges S, Desta Z, Li L et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74 (Pubitemid 43946844)
25. Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39
26. Murdter TE, Schroth W, Bacchus-Gerybadze L et al (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708-717
27. Ahern TP, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL (2009) No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 18:2562-2564
28. Kelly CM, Juurlink DN, Gomes T et al (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693
29. Azoulay L, Dell'Aniello S, Huiart L, du Fort GG, Suissa S (2011) Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat 126:695-703
30. Goetz MP, Knox SK, Suman VJ et al (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121 (Pubitemid 47555336)
31. Siegelmann-Danieli N, Kurnik D, Lomnicky Y et al (2011) Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 125:505-510
32. Dezentje VO, van Blijderveen NJC, Gelderblom H et al (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423-2429
33. Yu AM, Haining RL (2001) Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities? Drug Metab Dispos 29:1514-1520 (Pubitemid 33000701)
34. Leeder JS, Pearce RE, Gaedigk A, Modak A, Rosen DI (2008) Evaluation of a [(13)C]-dextromethorphan breath test to assess CYP2D6 phenotype. J Clin Pharmacol 48:1041-1051
35. Teunissen SF, Rosing H, Koornstra RH et al (2009) Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:2519-2529
36. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234-242
37. Modak AS (2007) Stable isotope breath tests in clinical medicine: a review. J Breath Res 4:017002
38. http://www.photal.co.jp/english/product/poc1-0.html. Visited Nov 5th 2012
39. de Graan AJ, Teunissen SF, de Vos FY et al (2011) Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol 29:3240-3246
40. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295 (Pubitemid 27058401)
41. Frank D, Jaehde U, Fuhr U (2007) Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 63:321-333 (Pubitemid 46399125)
42. Schoedel KA, Pope LE, Sellers EM (2012) Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. Clin Drug Investig 32:157-169
43. Wu AH, Lorizio W, Tchu S et al (2012) Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score. Breast Cancer Res Treat 133:677-683
44. Irvin WJ Jr, Walko CM, Weck KE et al (2011) Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 29:3232-3239
45. Kiyotani K, Mushiroda T, Imamura CK et al (2012) Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat 131:137-145
46. Ahmad A, Ali SM, Ahmad MU, Sheikh S, Ahmad I (2010) Orally administered endoxifen is a new therapeutic agent for breast cancer. Breast Cancer Res Treat 122:579-584
47. Ahmad A, Shahabuddin S, Sheikh S et al (2010) Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol Ther 88:814-817